{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319878540416.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/s0002-9394(02)01334-x"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S000293940201334X?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S000293940201334X?httpAccept=text/plain"}},{"identifier":{"@type":"NAID","@value":"30006677768"}}],"dc:title":[{"@value":"Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670319878540416","@type":"Researcher","foaf:name":[{"@value":"Rookaya Mather"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319878540418","@type":"Researcher","foaf:name":[{"@value":"Lisa M Karenchak"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319878540417","@type":"Researcher","foaf:name":[{"@value":"Eric G Romanowski"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319878540419","@type":"Researcher","foaf:name":[{"@value":"Regis P Kowalski"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00029394"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00029394"}],"prism:publicationName":[{"@value":"American Journal of Ophthalmology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2002-04","prism:volume":"133","prism:number":"4","prism:startingPage":"463","prism:endingPage":"466"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S000293940201334X?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S000293940201334X?httpAccept=text/plain"}],"createdAt":"2002-07-25","modifiedAt":"2025-09-11","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360848659410421504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Moxifloxacin as Postoperative Prophylaxis for\n                    <i>Enterococcus faecalis</i>\n                    -Induced Endophthalmitis After Cataract Surgery in Aphakic Rabbits"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204272431232","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacodynamic profile and clinical efficacy of moxifloxacin ophthalmic solution (VegamoxTM 0.5% ophthalmic solution)"},{"@language":"ja","@value":"モキシフロキサシン点眼液（ベガモックス点眼液０．５％）の薬理学的特性および臨床効果"},{"@value":"新薬紹介総説 モキシフロキサシン点眼液(ベガモックス点眼液0.5%)の薬理学的特性および臨床効果"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ モキシフロキサシン テンガンエキ ベガモックス テンガンエキ 0 5% ノ ヤクリガクテキ トクセイ オヨビ リンショウ コウカ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679216119168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of Staphylococcus Epidermidis Endophthalmitis with Intravitreal Moxifloxacin in a Rabbit Model"}]},{"@id":"https://cir.nii.ac.jp/crid/1520291853576120448","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"外眼部細菌性感染症由来の臨床分離株に対するモキシフロキサシンの抗菌活性"},{"@language":"ja-Kana","@value":"ガイガンブ サイキン セイカンセンショウ ユライ ノ リンショウ ブンリカブ ニ タイスル モキシフロキサシン ノ コウキン カッセイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1520573330220443264","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"ガチフロキサシンの眼科臨床分離株に対する抗菌力"},{"@language":"ja-Kana","@value":"ガチフロキサシン ノ ガンカ リンショウ ブンリカブ ニ タイスル コウキンリョク"}]},{"@id":"https://cir.nii.ac.jp/crid/1521980705880231552","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"点眼投与を想定したガチフロキサシンのPostantibiotic Effect"},{"@language":"ja-Kana","@value":"テンガン トウヨ オ ソウテイ シタ ガチフロキサシン ノ Postantibiotic Effect"}]},{"@id":"https://cir.nii.ac.jp/crid/1523388080639736576","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Laboratory investigation: A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model"},{"@language":"ja-Kana","@value":"Laboratory investigation A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone resistant Staphylococcus aureus rabbit model"}]},{"@id":"https://cir.nii.ac.jp/crid/1571980075314843136","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"感染性角膜炎の現況"},{"@language":"en","@value":"Present Status of Infectious Keratitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1571980075395128192","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"第4世代キノロン系抗菌点眼薬『モキシフロキサシン点眼液(ベガモックス^【○!R】点眼液0.5%)』の基礎的・臨床的特徴"},{"@language":"en","@value":"Basic and Clinical Characteristics of 4^<TH> Generation Quinolone Antibacterial Eyedrop Moxifloxacin Ophthalmic Solution (Vegamox^【○!R】 Ophthalmic Solution 0.5%)"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/s0002-9394(02)01334-x"},{"@type":"CIA","@value":"30006677768"},{"@type":"CROSSREF","@value":"10.1089/jop.2012.0149_references_DOI_1LFMSmoCwyFp17sMfcBFMYmP0LF"},{"@type":"CROSSREF","@value":"10.1620/tjem.205.223_references_DOI_1LFMSmoCwyFp17sMfcBFMYmP0LF"},{"@type":"CROSSREF","@value":"10.1254/fpj.129.375_references_DOI_1LFMSmoCwyFp17sMfcBFMYmP0LF"},{"@type":"CROSSREF","@value":"10.1007/s10384-008-0530-1_references_DOI_1LFMSmoCwyFp17sMfcBFMYmP0LF"}]}